NLY01在早期未治疗帕金森病中的安全性、耐受性和疗效:一项随机、双盲、安慰剂对照试验
这项36周、在美国58家运动障碍门诊开展的随机双盲安慰剂对照试验,将255例早期未治疗帕金森病患者按1:1:1分配至NLY01 2.5 mg、5.0 mg或安慰剂组。主要终点MDS-UPDRS II+III总分变化与安慰剂无显著差异,2.5 mg组差值-0.39(95%CI -2.96至2.18;p=0.77),5.0 mg组0.36(-2.28至3.00;p=0.79)。治疗不良事件三组相似,胃肠道反应常见。作者结论:NLY01未带来运动或非运动改善,亚组分析提示年轻患者可能运动获益,需进一步研究验证。
要点
- NLY01 2.5 mg和5.0 mg组MDS-UPDRS II+III总分变化与安慰剂无显著差异。
- 治疗不良事件三组相似,胃肠道反应在活性组更常见,恶心为最常见事件。
- 亚组分析提示年轻参与者可能运动获益,但需进一步研究验证。
核心结论
- NLY01 2.5 mg和5.0 mg与安慰剂相比,未使帕金森病运动或非运动特征改善。
- 亚组分析提出年轻参与者可能运动获益,需进一步研究确定这些探索性观察是否可重复。
研究设计与样本
- 36周、随机、双盲、安慰剂对照研究,在美国58家运动障碍门诊开展。
- 筛查447人,255例符合英国脑库或运动障碍学会研究标准的早期未治疗帕金森病患者随机分配(1:1:1)至NLY01 2.5 mg、5.0 mg或安慰剂组,每组85例。
- 主要分析人群为所有随机分配且至少接受一剂研究药物的参与者;安慰剂组1例未接受治疗,未纳入主要分析。
- 主要疗效终点为基线至第36周MDS-UPDRS第II部分和第III部分总分变化。
- 研究于2020年1月28日至2023年2月16日进行,注册号NCT04154072。
主要发现
- 第36周MDS-UPDRS II+III总分变化与安慰剂差值:2.5 mg组-0.39(95%CI -2.96至2.18;p=0.77),5.0 mg组0.36(95%CI -2.28至3.00;p=0.79)。
- 治疗不良事件:2.5 mg组71/85(84%),5.0 mg组79/85(93%),安慰剂组73/84(87%)。
- 胃肠道疾病:2.5 mg组52/85(61%),5.0 mg组64/85(75%),安慰剂组30/84(36%)。
- 恶心:2.5 mg组33/85(39%),5.0 mg组49/85(58%),安慰剂组16/84(19%)。
- 研究期间无死亡发生。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 亚组分析提出年轻参与者可能运动获益,需进一步研究确定这些探索性观察是否可重复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Converging lines of evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, justifying exploration of therapeutic agents thought to attenuate pathogenic microglial function. We sought to test the safety and efficacy of NLY01-a brain-penetrant, pegylated, longer-lasting version of exenatide (a glucagon-like peptide-1 receptor agonist) that is believed to be anti-inflammatory via reduction of microglia activation-in Parkinson's disease. METHODS: We report a 36-week, randomised, double-blind, placebo-controlled study of NLY01 in participants with early untreated Parkinson's disease conducted at 58 movement disorder clinics in the USA. Participants meeting UK Brain Bank or Movement Disorder Society research criteria for Parkinson's disease were randomly allocated (1:1:1) to one of two active treatment groups (2·5 mg or 5·0 mg NLY01) or matching placebo, based on a central computer-generated randomisation scheme using permuted block randomisation with varying block sizes. All participants, investigators, coordinators, study staff, and sponsor personnel were masked to treatment assignments throughout the study. The primary efficacy endpoint for the primary analysis population (defined as all randomly assigned participants who received at least one dose of study drug) was change from baseline to week 36 in the sum of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III. Safety was assessed in the safety population (all randomly allocated participants who received at least one dose of the study drug) with documentation of adverse events, vital signs, electrocardiograms, clinical laboratory assessments, physical examination, and scales for suicidality, sleepiness, impulsivity, and depression. This trial is complete and registered at ClinicalTrials.gov, NCT04154072. FINDINGS: The study took place between Jan 28, 2020, and Feb 16, 2023. 447 individuals were screened, of whom 255 eligible participants were randomly assigned (85 to each study group). One patient assigned to placebo did not receive study treatment and was not included in the primary analysis. At 36 weeks, 2·5 mg and 5·0 mg NLY01 did not differ from placebo with respect to change in sum scores on MDS-UPDRS parts II and III: difference versus placebo -0·39 (95% CI -2·96 to 2·18; p=0·77) for 2·5 mg and 0·36 (-2·28 to 3·00; p=0·79) for 5·0 mg. Treatment-emergent adverse events were similar across groups (reported in 71 [84%] of 85 patients on 2·5 mg NLY01, 79 [93%] of 85 on 5·0 mg, and 73 [87%] of 84 on placebo), with gastrointestinal disorders the most commonly observed class in active groups (52 [61%] for 2·5 mg, 64 [75%] for 5·0 mg, and 30 [36%] for placebo) and nausea the most common event overall (33 [39%] for 2·5 mg, 49 [58%] for 5·0 mg, and 16 [19%] for placebo). No deaths occurred during the study. INTERPRETATION: NLY01 at 2·5 and 5·0 mg was not associated with any improvement in Parkinson's disease motor or non-motor features compared with placebo. A subgroup analysis raised the possibility of motor benefit in younger participants. Further study is needed to determine whether these exploratory observations are replicable. FUNDING: D&D Pharmatech-Neuraly.
引用
- McGarry A, Rosanbalm S, Leinonen M, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024. PMID: 38101901. doi:10.1016/S1474-4422(23)00378-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。